Amgen Inc (AMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH3778D
- Pages: 257
- October 2018
- Total Views:1228
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.
Amgen Inc (AMGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 10
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Amgen Inc, Pharmaceuticals & Healthcare, Deal Details 23
Asset Purchase 23
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23
Venture Financing 25
Immatics Biotech Raises USD58 Million in Series E Financing 25
SiteOne Therapeutics Raises USD15 Million in Series B Financing 26
Dezima Pharma Raises USD 13 Million In Series A Financing 28
Dezima Pharma Raises Funds Through Seed Financing 29
Gamida Cell Raises USD 10 Million In Series E Financing 30
Partnerships 32
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32
GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33
Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34
Amgen and MD Anderson Enter Two Collaboration Agreements 35
Nuvelution Pharma Enters into Agreement with Amgen 36
Amgen Enters into Research Agreement with Boston Children's Hospital 37
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38
Amgen and Simcere Pharma Enter into Co-Development Agreement 39
Amgen and Array BioPharma Enter into Agreement 40
Elasmogen, Feldan Bio Enter into Agreement with Amgen 41
SiteOne Therapeutics Enters into R&D Agreement with Amgen 42
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43
Nuevolution Enters into Research Agreement with Amgen 44
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46
Amgen Forms Partnership with Advaxis 47
Amgen Enters into Agreement with Allergan 48
Amgen and Daiichi Sankyo Enter into Agreement 49
Flatiron Health Partners with Amgen 50
Amgen and Merck Enter into Agreement 51
Amgen Expands its Co-Development Agreement with Novartis 52
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53
Amgen Enters into Research Agreement with MD Anderson 54
Biodesy Enters into Research Agreement with Amgen 55
Innovative Targeting Solutions Enters into Research Agreement with Amgen 56
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59
Amgen and Astellas Pharma Form Joint Venture 60
Amgen Forms Joint Venture With Zhejiang Beta Pharma 61
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65
Amgen Enters Into Co-Development Agreement With Astellas 66
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71
Dako Enters Into Co-Development Agreement With Amgen 73
Dako Enters Into Co-Development Agreement With Amgen 74
Merger 75
AstraZeneca Rumored To Merge With Amgen 75
Licensing Agreements 76
Amgen Exercises Option for Licensing Agreement with Nuevolution 76
Akero Therapeutics Enters into Licensing Agreement with Amgen 78
Amgen Enters into Licensing Agreement with Carmot Therapeutics 79
Amgen Enters into Licensing Agreement with Ligand Pharma 80
Amgen Enters into Licensing Agreement with Immatics Biotech 81
Amgen Enters into Licensing Agreement with Teijin Pharma 82
Amgen Enters into Licensing Agreement with Arrowhead Pharma 83
Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84
Amgen Enters into Licensing Agreement with Xencor 85
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87
FLX Bio Enters Into Licensing Agreement with Amgen 88
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91
Amgen Enters into Licensing Agreement with Kite Pharma 92
Cancer Research UK Enters into Licensing Agreement with Amgen 94
Amgen Expands its Licensing Agreement with Carmot Therapeutics 95
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102
Roche Enters into Licensing Agreement with Amgen 103
Open Monoclonal Enters into Licensing Agreement with Amgen 104
Amgen Enters Into Licensing Agreement With R-Pharm 105
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109
Selexis Expands License Agreement With Amgen 110
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112
Equity Offering 113
Arrowhead Pharma to Raise Funds through Public Offering of Shares 113
Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114
Debt Offering 115
Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115
Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117
Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119
Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120
Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121
Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122
Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123
Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124
Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125
Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126
Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127
Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128
Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138
Asset Transactions 140
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140
Acquisition 141
Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141
Amgen to Acquire Catherex from Medigene 142
Amgen Acquires Dezima Pharma 143
Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145
Biocad Rumored To Sell Itself For Up To USD 1 Billion 147
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148
Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152
Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153
Amgen Inc - Key Competitors 155
Amgen Inc - Key Employees 156
Amgen Inc - Locations And Subsidiaries 158
Head Office 158
Other Locations & Subsidiaries 158
Joint Venture 163
Recent Developments 165
Strategy And Business Planning 165
Jul 31, 2018: Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island 165
Apr 10, 2018: Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant 166
Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 167
Financial Announcements 168
Jul 26, 2018: Amgen reports second quarter 2018 Financial Results 168
Apr 24, 2018: Amgen Announces First Quarter 2018 Financial Results 171
Feb 01, 2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results 173
Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 176
Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 178
Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 180
Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 183
Corporate Communications 186
Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires 186
Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 187
Sep 22, 2017: Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 188
Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 189
Legal and Regulatory 190
Jun 13, 2017: US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines 190
Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 191
Government and Public Interest 192
Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 192
Aug 23, 2017: Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease 193
Product News 194
12/05/2017: Xencor Receives Milestone Payment from Amgen 194
11/17/2017: Amgen Launches The ENBREL Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjector That Is Ergonomically Designed For Patients 195
11/10/2017: Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer 196
09/14/2017: FDA Approves Amgen And Allergan's MVASI (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer 197
07/11/2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children 198
07/03/2017: Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA Subcutaneous Injection 60mg Syringe 200
06/23/2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia 201
06/08/2018: European Commission Approves Prolia (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis 202
05/21/2018: Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass 203
05/21/2018: FDA Approves Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis 204
04/27/2018: Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis 205
04/02/2018: FDA Approves First Therapy for Patients with MRD-Positive ALL 207
03/29/2018: FDA Approves BLINCYTO (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children 208
03/29/2017: FDA Grants Priority Review For Amgen's BLINCYTO (blinatumomab) Supplemental Biologics License Application 210
03/06/2017: Amgen to Present New Data on Omecamtiv Mecarbil at the American College of Cardiology 66th Annual Scientific Session 212
02/23/2018: Amgen Receives Positive Opinion Expanding Use Of XGEVA (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe 213
02/15/2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis 214
02/07/2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis 215
Jan 23, 2018: Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model 217
01/16/2017: The Scottish Medicines Consortium declines two life-prolonging myeloma treatments 218
01/05/2018: FDA Approves XGEVA (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma 219
Product Approvals 220
Jan 09, 2018: Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE) Antibody Construct Blinatumomab for Relapsed or Refractory B- cell Precursor Acute Lymphoblastic Leukemia in Japan 220
Nov 27, 2017: Amgen Europe: Withdrawal of the Marketing Authorisation Application for Biosimilar Bevacizumab (Kyomarc) 221
Oct 09, 2017: FDA Accepts Supplemental Biologics License Application For Prolia (Denosumab) In Glucocorticoid-Induced Osteoporosis 222
Sep 11, 2017: Amgen's Parsabiv Rejects For Use Within NHS Scotland 223
Jul 31, 2017: Amgen Submits Supplemental Biologics License Application For Prolia (denosumab) In Glucocorticoid-Induced Osteoporosis 224
Jun 07, 2017: Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab 225
Mar 06, 2017: Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO 226
Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 227
Jan 27, 2017: Withdrawal of the application for a change to the marketing authorisation for Xgeva (denosumab) 229
Clinical Trials 230
Feb 14, 2018: Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO (blinatumomab) 230
Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology 231
Feb 02, 2018: Daiichi Sankyo Announces Update on Amgen's Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment 233
Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting 234
Jul 13, 2017: Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin (bevacizumab) 236
Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association 237
Jun 20, 2017: Neurotech Announces Positive Phase 2 Results in NT-501 for Macular Telangiectasia 238
Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting 239
Apr 07, 2017: Osteoporosis drug found safe in long-term trial 240
Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) 241
Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia 242
Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 244
Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 245
Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy 246
Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 248
Jan 10, 2017: Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis 249
Other Significant Developments 251
Sep 20, 2018: Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA 251
Sep 05, 2018: Amgen and LabCentral open nomination process for Lab Residency 252
Jun 05, 2018: Preventing Infections in Cancer Patients Program to Launch Innovative Tools to Improve Patient-Provider Conversations 253
Mar 08, 2018: Amgen Announces Final Results Of Tender Offer 254
Mar 06, 2018: Amgen Announces Preliminary Results Of Tender Offer 255
Jan 09, 2018: BC Platforms to Provide Big Data Driven Research Solutions to Amgen in Cardiovascular Diseases and Oncology 256
Oct 06, 2017: Amgen And LabCentral Open Nomination Process For Lab Residency 257
Sep 25, 2017: Amgen Provides Update On Hurricane Maria 258
Appendix 259
Methodology 259
About GlobalData 259
Contact Us 259
Disclaimer 259
List Of Figure
List of Figures
Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16
List Of Table
List of Tables
Amgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Amgen Inc, Deals By Therapy Area, 2012 to YTD 2018 14
Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23
Immatics Biotech Raises USD58 Million in Series E Financing 25
SiteOne Therapeutics Raises USD15 Million in Series B Financing 26
Dezima Pharma Raises USD 13 Million In Series A Financing 28
Dezima Pharma Raises Funds Through Seed Financing 29
Gamida Cell Raises USD 10 Million In Series E Financing 30
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32
GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33
Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34
Amgen and MD Anderson Enter Two Collaboration Agreements 35
Nuvelution Pharma Enters into Agreement with Amgen 36
Amgen Enters into Research Agreement with Boston Children's Hospital 37
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38
Amgen and Simcere Pharma Enter into Co-Development Agreement 39
Amgen and Array BioPharma Enter into Agreement 40
Elasmogen, Feldan Bio Enter into Agreement with Amgen 41
SiteOne Therapeutics Enters into R&D Agreement with Amgen 42
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43
Nuevolution Enters into Research Agreement with Amgen 44
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46
Amgen Forms Partnership with Advaxis 47
Amgen Enters into Agreement with Allergan 48
Amgen and Daiichi Sankyo Enter into Agreement 49
Flatiron Health Partners with Amgen 50
Amgen and Merck Enter into Agreement 51
Amgen Expands its Co-Development Agreement with Novartis 52
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53
Amgen Enters into Research Agreement with MD Anderson 54
Biodesy Enters into Research Agreement with Amgen 55
Innovative Targeting Solutions Enters into Research Agreement with Amgen 56
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59
Amgen and Astellas Pharma Form Joint Venture 60
Amgen Forms Joint Venture With Zhejiang Beta Pharma 61
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65
Amgen Enters Into Co-Development Agreement With Astellas 66
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71
Dako Enters Into Co-Development Agreement With Amgen 73
Dako Enters Into Co-Development Agreement With Amgen 74
AstraZeneca Rumored To Merge With Amgen 75
Amgen Exercises Option for Licensing Agreement with Nuevolution 76
Akero Therapeutics Enters into Licensing Agreement with Amgen 78
Amgen Enters into Licensing Agreement with Carmot Therapeutics 79
Amgen Enters into Licensing Agreement with Ligand Pharma 80
Amgen Enters into Licensing Agreement with Immatics Biotech 81
Amgen Enters into Licensing Agreement with Teijin Pharma 82
Amgen Enters into Licensing Agreement with Arrowhead Pharma 83
Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84
Amgen Enters into Licensing Agreement with Xencor 85
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87
FLX Bio Enters Into Licensing Agreement with Amgen 88
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91
Amgen Enters into Licensing Agreement with Kite Pharma 92
Cancer Research UK Enters into Licensing Agreement with Amgen 94
Amgen Expands its Licensing Agreement with Carmot Therapeutics 95
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102
Roche Enters into Licensing Agreement with Amgen 103
Open Monoclonal Enters into Licensing Agreement with Amgen 104
Amgen Enters Into Licensing Agreement With R-Pharm 105
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109
Selexis Expands License Agreement With Amgen 110
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112
Arrowhead Pharma to Raise Funds through Public Offering of Shares 113
Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114
Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115
Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117
Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119
Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120
Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121
Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122
Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123
Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124
Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125
Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126
Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127
Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128
Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140
Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141
Amgen to Acquire Catherex from Medigene 142
Amgen Acquires Dezima Pharma 143
Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145
Biocad Rumored To Sell Itself For Up To USD 1 Billion 147
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148
Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152
Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153
Amgen Inc, Key Competitors 155
Amgen Inc, Key Employees 156
Amgen Inc, Other Locations 158
Amgen Inc, Subsidiaries 160
Amgen Inc, Joint Venture 163
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Amgen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.
Amgen Inc (AMGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 10
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Amgen Inc, Pharmaceuticals & Healthcare, Deal Details 23
Asset Purchase 23
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23
Venture Financing 25
Immatics Biotech Raises USD58 Million in Series E Financing 25
SiteOne Therapeutics Raises USD15 Million in Series B Financing 26
Dezima Pharma Raises USD 13 Million In Series A Financing 28
Dezima Pharma Raises Funds Through Seed Financing 29
Gamida Cell Raises USD 10 Million In Series E Financing 30
Partnerships 32
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32
GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33
Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34
Amgen and MD Anderson Enter Two Collaboration Agreements 35
Nuvelution Pharma Enters into Agreement with Amgen 36
Amgen Enters into Research Agreement with Boston Children's Hospital 37
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38
Amgen and Simcere Pharma Enter into Co-Development Agreement 39
Amgen and Array BioPharma Enter into Agreement 40
Elasmogen, Feldan Bio Enter into Agreement with Amgen 41
SiteOne Therapeutics Enters into R&D Agreement with Amgen 42
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43
Nuevolution Enters into Research Agreement with Amgen 44
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46
Amgen Forms Partnership with Advaxis 47
Amgen Enters into Agreement with Allergan 48
Amgen and Daiichi Sankyo Enter into Agreement 49
Flatiron Health Partners with Amgen 50
Amgen and Merck Enter into Agreement 51
Amgen Expands its Co-Development Agreement with Novartis 52
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53
Amgen Enters into Research Agreement with MD Anderson 54
Biodesy Enters into Research Agreement with Amgen 55
Innovative Targeting Solutions Enters into Research Agreement with Amgen 56
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59
Amgen and Astellas Pharma Form Joint Venture 60
Amgen Forms Joint Venture With Zhejiang Beta Pharma 61
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65
Amgen Enters Into Co-Development Agreement With Astellas 66
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71
Dako Enters Into Co-Development Agreement With Amgen 73
Dako Enters Into Co-Development Agreement With Amgen 74
Merger 75
AstraZeneca Rumored To Merge With Amgen 75
Licensing Agreements 76
Amgen Exercises Option for Licensing Agreement with Nuevolution 76
Akero Therapeutics Enters into Licensing Agreement with Amgen 78
Amgen Enters into Licensing Agreement with Carmot Therapeutics 79
Amgen Enters into Licensing Agreement with Ligand Pharma 80
Amgen Enters into Licensing Agreement with Immatics Biotech 81
Amgen Enters into Licensing Agreement with Teijin Pharma 82
Amgen Enters into Licensing Agreement with Arrowhead Pharma 83
Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84
Amgen Enters into Licensing Agreement with Xencor 85
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87
FLX Bio Enters Into Licensing Agreement with Amgen 88
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91
Amgen Enters into Licensing Agreement with Kite Pharma 92
Cancer Research UK Enters into Licensing Agreement with Amgen 94
Amgen Expands its Licensing Agreement with Carmot Therapeutics 95
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102
Roche Enters into Licensing Agreement with Amgen 103
Open Monoclonal Enters into Licensing Agreement with Amgen 104
Amgen Enters Into Licensing Agreement With R-Pharm 105
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109
Selexis Expands License Agreement With Amgen 110
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112
Equity Offering 113
Arrowhead Pharma to Raise Funds through Public Offering of Shares 113
Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114
Debt Offering 115
Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115
Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117
Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119
Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120
Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121
Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122
Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123
Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124
Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125
Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126
Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127
Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128
Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138
Asset Transactions 140
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140
Acquisition 141
Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141
Amgen to Acquire Catherex from Medigene 142
Amgen Acquires Dezima Pharma 143
Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145
Biocad Rumored To Sell Itself For Up To USD 1 Billion 147
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148
Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152
Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153
Amgen Inc - Key Competitors 155
Amgen Inc - Key Employees 156
Amgen Inc - Locations And Subsidiaries 158
Head Office 158
Other Locations & Subsidiaries 158
Joint Venture 163
Recent Developments 165
Strategy And Business Planning 165
Jul 31, 2018: Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island 165
Apr 10, 2018: Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant 166
Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 167
Financial Announcements 168
Jul 26, 2018: Amgen reports second quarter 2018 Financial Results 168
Apr 24, 2018: Amgen Announces First Quarter 2018 Financial Results 171
Feb 01, 2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results 173
Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 176
Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 178
Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 180
Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 183
Corporate Communications 186
Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires 186
Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 187
Sep 22, 2017: Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 188
Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 189
Legal and Regulatory 190
Jun 13, 2017: US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines 190
Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 191
Government and Public Interest 192
Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 192
Aug 23, 2017: Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease 193
Product News 194
12/05/2017: Xencor Receives Milestone Payment from Amgen 194
11/17/2017: Amgen Launches The ENBREL Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjector That Is Ergonomically Designed For Patients 195
11/10/2017: Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer 196
09/14/2017: FDA Approves Amgen And Allergan's MVASI (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer 197
07/11/2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children 198
07/03/2017: Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA Subcutaneous Injection 60mg Syringe 200
06/23/2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia 201
06/08/2018: European Commission Approves Prolia (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis 202
05/21/2018: Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass 203
05/21/2018: FDA Approves Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis 204
04/27/2018: Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis 205
04/02/2018: FDA Approves First Therapy for Patients with MRD-Positive ALL 207
03/29/2018: FDA Approves BLINCYTO (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children 208
03/29/2017: FDA Grants Priority Review For Amgen's BLINCYTO (blinatumomab) Supplemental Biologics License Application 210
03/06/2017: Amgen to Present New Data on Omecamtiv Mecarbil at the American College of Cardiology 66th Annual Scientific Session 212
02/23/2018: Amgen Receives Positive Opinion Expanding Use Of XGEVA (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe 213
02/15/2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis 214
02/07/2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis 215
Jan 23, 2018: Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model 217
01/16/2017: The Scottish Medicines Consortium declines two life-prolonging myeloma treatments 218
01/05/2018: FDA Approves XGEVA (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma 219
Product Approvals 220
Jan 09, 2018: Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE) Antibody Construct Blinatumomab for Relapsed or Refractory B- cell Precursor Acute Lymphoblastic Leukemia in Japan 220
Nov 27, 2017: Amgen Europe: Withdrawal of the Marketing Authorisation Application for Biosimilar Bevacizumab (Kyomarc) 221
Oct 09, 2017: FDA Accepts Supplemental Biologics License Application For Prolia (Denosumab) In Glucocorticoid-Induced Osteoporosis 222
Sep 11, 2017: Amgen's Parsabiv Rejects For Use Within NHS Scotland 223
Jul 31, 2017: Amgen Submits Supplemental Biologics License Application For Prolia (denosumab) In Glucocorticoid-Induced Osteoporosis 224
Jun 07, 2017: Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab 225
Mar 06, 2017: Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO 226
Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 227
Jan 27, 2017: Withdrawal of the application for a change to the marketing authorisation for Xgeva (denosumab) 229
Clinical Trials 230
Feb 14, 2018: Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO (blinatumomab) 230
Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology 231
Feb 02, 2018: Daiichi Sankyo Announces Update on Amgen's Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment 233
Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting 234
Jul 13, 2017: Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin (bevacizumab) 236
Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association 237
Jun 20, 2017: Neurotech Announces Positive Phase 2 Results in NT-501 for Macular Telangiectasia 238
Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting 239
Apr 07, 2017: Osteoporosis drug found safe in long-term trial 240
Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) 241
Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia 242
Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 244
Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 245
Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy 246
Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 248
Jan 10, 2017: Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis 249
Other Significant Developments 251
Sep 20, 2018: Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA 251
Sep 05, 2018: Amgen and LabCentral open nomination process for Lab Residency 252
Jun 05, 2018: Preventing Infections in Cancer Patients Program to Launch Innovative Tools to Improve Patient-Provider Conversations 253
Mar 08, 2018: Amgen Announces Final Results Of Tender Offer 254
Mar 06, 2018: Amgen Announces Preliminary Results Of Tender Offer 255
Jan 09, 2018: BC Platforms to Provide Big Data Driven Research Solutions to Amgen in Cardiovascular Diseases and Oncology 256
Oct 06, 2017: Amgen And LabCentral Open Nomination Process For Lab Residency 257
Sep 25, 2017: Amgen Provides Update On Hurricane Maria 258
Appendix 259
Methodology 259
About GlobalData 259
Contact Us 259
Disclaimer 259
List Of Figure
List of Figures
Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14
Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16
List Of Table
List of Tables
Amgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11
Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12
Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13
Amgen Inc, Deals By Therapy Area, 2012 to YTD 2018 14
Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16
Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17
Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23
Immatics Biotech Raises USD58 Million in Series E Financing 25
SiteOne Therapeutics Raises USD15 Million in Series B Financing 26
Dezima Pharma Raises USD 13 Million In Series A Financing 28
Dezima Pharma Raises Funds Through Seed Financing 29
Gamida Cell Raises USD 10 Million In Series E Financing 30
Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32
GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33
Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34
Amgen and MD Anderson Enter Two Collaboration Agreements 35
Nuvelution Pharma Enters into Agreement with Amgen 36
Amgen Enters into Research Agreement with Boston Children's Hospital 37
Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38
Amgen and Simcere Pharma Enter into Co-Development Agreement 39
Amgen and Array BioPharma Enter into Agreement 40
Elasmogen, Feldan Bio Enter into Agreement with Amgen 41
SiteOne Therapeutics Enters into R&D Agreement with Amgen 42
Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43
Nuevolution Enters into Research Agreement with Amgen 44
Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46
Amgen Forms Partnership with Advaxis 47
Amgen Enters into Agreement with Allergan 48
Amgen and Daiichi Sankyo Enter into Agreement 49
Flatiron Health Partners with Amgen 50
Amgen and Merck Enter into Agreement 51
Amgen Expands its Co-Development Agreement with Novartis 52
Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53
Amgen Enters into Research Agreement with MD Anderson 54
Biodesy Enters into Research Agreement with Amgen 55
Innovative Targeting Solutions Enters into Research Agreement with Amgen 56
Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57
NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59
Amgen and Astellas Pharma Form Joint Venture 60
Amgen Forms Joint Venture With Zhejiang Beta Pharma 61
Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63
Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64
Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65
Amgen Enters Into Co-Development Agreement With Astellas 66
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67
Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68
Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69
Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71
Dako Enters Into Co-Development Agreement With Amgen 73
Dako Enters Into Co-Development Agreement With Amgen 74
AstraZeneca Rumored To Merge With Amgen 75
Amgen Exercises Option for Licensing Agreement with Nuevolution 76
Akero Therapeutics Enters into Licensing Agreement with Amgen 78
Amgen Enters into Licensing Agreement with Carmot Therapeutics 79
Amgen Enters into Licensing Agreement with Ligand Pharma 80
Amgen Enters into Licensing Agreement with Immatics Biotech 81
Amgen Enters into Licensing Agreement with Teijin Pharma 82
Amgen Enters into Licensing Agreement with Arrowhead Pharma 83
Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84
Amgen Enters into Licensing Agreement with Xencor 85
NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87
FLX Bio Enters Into Licensing Agreement with Amgen 88
Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89
Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90
NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91
Amgen Enters into Licensing Agreement with Kite Pharma 92
Cancer Research UK Enters into Licensing Agreement with Amgen 94
Amgen Expands its Licensing Agreement with Carmot Therapeutics 95
Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96
ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100
Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102
Roche Enters into Licensing Agreement with Amgen 103
Open Monoclonal Enters into Licensing Agreement with Amgen 104
Amgen Enters Into Licensing Agreement With R-Pharm 105
Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107
Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109
Selexis Expands License Agreement With Amgen 110
Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111
DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112
Arrowhead Pharma to Raise Funds through Public Offering of Shares 113
Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114
Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115
Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116
Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117
Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119
Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120
Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121
Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122
Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123
Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124
Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125
Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126
Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127
Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128
Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130
Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132
Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134
Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136
Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140
Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141
Amgen to Acquire Catherex from Medigene 142
Amgen Acquires Dezima Pharma 143
Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145
Biocad Rumored To Sell Itself For Up To USD 1 Billion 147
Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148
Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150
Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152
Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153
Amgen Inc, Key Competitors 155
Amgen Inc, Key Employees 156
Amgen Inc, Other Locations 158
Amgen Inc, Subsidiaries 160
Amgen Inc, Joint Venture 163
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Amgen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 99224 42855 
Related Reports
Page 108 | 
May 2021
Page 74 | May 2021
Page 130 | March 2021
Page 140 | November 2020
Page 99 | July 2020